Full Press Release Details
CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL ), a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter , Ph.D., Chief Executive Officer, will participate in a virtual fireside chat during the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference on Thursday, April 14, 2022 , at 9:00 a.m. ET .
A live webcast will be available in the investor section of the company's website at www.nuvalent.com , and archived for 30 days following the presentation.
SOURCE Nuvalent, Inc.